Compare GPMT & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPMT | XLO |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.7M | 56.9M |
| IPO Year | 2017 | 2021 |
| Metric | GPMT | XLO |
|---|---|---|
| Price | $0.86 | $9.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | $3.00 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 287.8K | 8.3K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | ★ 12.99% | N/A |
| EPS Growth | ★ 73.58 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $43,766,000.00 |
| Revenue This Year | $458.85 | N/A |
| Revenue Next Year | $8.63 | $168.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 589.88 |
| 52 Week Low | $0.84 | $0.46 |
| 52 Week High | $3.06 | $9.90 |
| Indicator | GPMT | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 26.91 | 49.23 |
| Support Level | N/A | $8.52 |
| Resistance Level | $1.56 | $9.15 |
| Average True Range (ATR) | 0.05 | 0.29 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 10.67 | 46.74 |
Granite Point Mortgage Trust Inc focuses on directly originating, investing in, and managing senior floating rate commercial mortgage loans and other debt and debt-like commercial real estate investments. The company constructs its investment portfolio on a loan-by-loan basis, emphasizing rigorous credit underwriting, selectivity, and diversification, and assesses each investment from a fundamental value perspective relative to other opportunities available in the market. It typically provides intermediate-term bridge or transitional financing for a variety of purposes, including acquisitions, recapitalizations, refinancing, and a range of business plans, including lease-up, renovation, repositioning and repurposing of the commercial property.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.